Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alt-2074 SCHEMBL921152 | 0.68 | BCHE (0.31) | BCHEACHEPDK2PDK4 | |
| Alt-2074 SCHEMBL29379070 | 0.68 | BCHE (0.31) | BCHEACHEPDK2PDK4 | |
| SCHEMBL7768071 | 0.67 | PGR (0.31) | — | |
| SCHEMBL2191872 | 0.64 | PDK2 (0.41) | PDK2PDK4HTR5A | |
| SCHEMBL22010250 | 0.64 | PDK2 (0.46) | BCHEACHEPDK2PDK4HTR5A | |
| SCHEMBL24338265 | 0.59 | PDK2 (0.40) | ACHEPDK2PDK4HTR5A | |
| SCHEMBL1627657 | 0.59 | HTR2A (0.48) | ACHEPDK2PDK4HTR5A | |
| SCHEMBL29392540 | 0.59 | HTR2A (0.48) | ACHEPDK2PDK4HTR5A | |
| SCHEMBL28880724 | 0.59 | PDK2 (0.40) | ACHEPDK2PDK4HTR5A | |
| SCHEMBL29533669 | 0.59 | PDK2 (0.40) | ACHEPDK2PDK4HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0701554-B1 | NOVEL COMPOUNDS HAVING A BENZISOSELEN-AZOLINE AND -AZINE STRUCTURE, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | OXIS ISLE OF MAN LTD (GB) | 2001-06-27 | — | — | EP | claimed |
| US-5968920-A | INCREASE GLUTATHIONE PEROXIDASE ACTIVITY FOR REDUCING LEVELS OF PEROXIDES IN CELLS OR TISSUES | OXIS ISLE OF MAN, LIMITED (US) | 1999-10-19 | — | — | US | claimed |
| US-20110288013-A1 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2011-11-24 | — | — | US | disclosed |
| EP-2215262-A2 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2010-08-11 | — | — | EP | disclosed |
| US-20090246770-A1 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-10-01 | — | — | US | disclosed |
| WO-2009057119-A2 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-05-07 | — | — | WO | disclosed |
| EP-0701554-B1 | NOVEL COMPOUNDS HAVING A BENZISOSELEN-AZOLINE AND -AZINE STRUCTURE, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | OXIS ISLE OF MAN LTD (GB) | 2001-06-27 | — | — | EP | disclosed |
| US-6093532-A | USING ADAPTED STORAGE MEDIUM WHICH SUPPLIES SELENIUM FOR GLUTATHIONE PEROXIDASE, A CRYOPROTECTIVE AND ANTIOXIDANT ENZYME | OXIS ISLE OF MAN, LIMITED (US) | 2000-07-25 | — | — | US | disclosed |
| US-5968920-A | INCREASE GLUTATHIONE PEROXIDASE ACTIVITY FOR REDUCING LEVELS OF PEROXIDES IN CELLS OR TISSUES | OXIS ISLE OF MAN, LIMITED (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0701554-A1 | NOVEL COMPOUNDS HAVING A BENZISOSELEN-AZOLINE AND -AZINE STRUCTURE, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | OXIS INTERNATIONAL S.A. (FR) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995027706-A1 | NOVEL COMPOUNDS HAVING A BENZISOSELEN-AZOLINE AND -AZINE STRUCTURE, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | OXIS INTERNATIONAL S.A. (FR) | 1995-10-19 | — | — | WO | disclosed |